Modelling Patient Drug Exposure Profiles in Vitro to Narrow the Valley of Death
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Chi L, Burrows A, Anderson R
. Can preclinical drug development help to predict adverse events in clinical trials?. Drug Discov Today. 2021; 27(1):257-268.
DOI: 10.1016/j.drudis.2021.08.010.
View
2.
Thiemicke A, Jashnsaz H, Li G, Neuert G
. Generating kinetic environments to study dynamic cellular processes in single cells. Sci Rep. 2019; 9(1):10129.
PMC: 6625993.
DOI: 10.1038/s41598-019-46438-8.
View
3.
Petreus T, Cadogan E, Hughes G, Smith A, Pilla Reddy V, Lau A
. Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response. Commun Biol. 2021; 4(1):1001.
PMC: 8385015.
DOI: 10.1038/s42003-021-02526-y.
View
4.
Sun D, Gao W, Hu H, Zhou S
. Why 90% of clinical drug development fails and how to improve it?. Acta Pharm Sin B. 2022; 12(7):3049-3062.
PMC: 9293739.
DOI: 10.1016/j.apsb.2022.02.002.
View
5.
Jashnsaz H, Fox Z, Hughes J, Li G, Munsky B, Neuert G
. Diverse Cell Stimulation Kinetics Identify Predictive Signal Transduction Models. iScience. 2020; 23(10):101565.
PMC: 7549069.
DOI: 10.1016/j.isci.2020.101565.
View